GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Change In Payables And Accrued Expense

Cibus (CBUS) Change In Payables And Accrued Expense : $-2.24 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cibus Change In Payables And Accrued Expense?

Cibus's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $0.69 Mil. It means Cibus's Accounts Payable & Accrued Expense increased by $0.69 Mil from Dec. 2023 to Mar. 2024 .

Cibus's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-2.06 Mil. It means Cibus's Accounts Payable & Accrued Expense declined by $2.06 Mil from Dec. 2022 to Dec. 2023 .


Cibus Change In Payables And Accrued Expense Historical Data

The historical data trend for Cibus's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Change In Payables And Accrued Expense Chart

Cibus Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only 0.80 0.20 -2.90 -0.40 -2.06

Cibus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.87 -1.84 2.27 -3.36 0.69

Cibus Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Cibus's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cibus (CBUS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Change In Payables And Accrued Expense
Traded in Other Exchanges
N/A
Address
6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.
Executives
Rory B Riggs director, officer: Chief Executive Officer 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr. director 1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn 10 percent owner C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante director SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn director VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann director 21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker director 13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King officer: Chief Financial Officer 750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William officer: See Remarks 13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham director, officer: See Remarks 6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill director C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr director, officer: President and CEO 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak officer: Chief Financial Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter officer: Chief Business Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas officer: Chief Science Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113